These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 30877737)
1. Biochemical diagnosis of vascular cognitive impairment associated with subcortical small vessels disease. Liakakis G Hell J Nucl Med; 2019; 22 Suppl():187-193. PubMed ID: 30877737 [TBL] [Abstract][Full Text] [Related]
2. Update on Vascular Cognitive Impairment Associated with Subcortical Small-Vessel Disease. Wallin A; Román GC; Esiri M; Kettunen P; Svensson J; Paraskevas GP; Kapaki E J Alzheimers Dis; 2018; 62(3):1417-1441. PubMed ID: 29562536 [TBL] [Abstract][Full Text] [Related]
3. Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus report. Wallin A; Kapaki E; Boban M; Engelborghs S; Hermann DM; Huisa B; Jonsson M; Kramberger MG; Lossi L; Malojcic B; Mehrabian S; Merighi A; Mukaetova-Ladinska EB; Paraskevas GP; Popescu BO; Ravid R; Traykov L; Tsivgoulis G; Weinstein G; Korczyn A; Bjerke M; Rosenberg G BMC Neurol; 2017 May; 17(1):102. PubMed ID: 28535786 [TBL] [Abstract][Full Text] [Related]
4. Blood-brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein-β in patients with subcortical small-vessel disease. Kettunen P; Bjerke M; Eckerström C; Jonsson M; Zetterberg H; Blennow K; Svensson J; Wallin A Alzheimers Dement (Amst); 2022; 14(1):e12296. PubMed ID: 35356486 [TBL] [Abstract][Full Text] [Related]
5. Potential of brain age in identifying early cognitive impairment in subcortical small-vessel disease patients. Shi Y; Mao H; Gao Q; Xi G; Zeng S; Ma L; Zhang X; Li L; Wang Z; Ji W; He P; You Y; Chen K; Shao J; Mao X; Fang X; Wang F Front Aging Neurosci; 2022; 14():973054. PubMed ID: 36118707 [TBL] [Abstract][Full Text] [Related]
6. Obstructive Sleep Apnea is Associated With Early but Possibly Modifiable Alzheimer's Disease Biomarkers Changes. Liguori C; Mercuri NB; Izzi F; Romigi A; Cordella A; Sancesario G; Placidi F Sleep; 2017 May; 40(5):. PubMed ID: 28329084 [TBL] [Abstract][Full Text] [Related]
7. Consensus statement for diagnosis of subcortical small vessel disease. Rosenberg GA; Wallin A; Wardlaw JM; Markus HS; Montaner J; Wolfson L; Iadecola C; Zlokovic BV; Joutel A; Dichgans M; Duering M; Schmidt R; Korczyn AD; Grinberg LT; Chui HC; Hachinski V J Cereb Blood Flow Metab; 2016 Jan; 36(1):6-25. PubMed ID: 26198175 [TBL] [Abstract][Full Text] [Related]
8. Shared CSF Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus and Subcortical Small Vessel Disease. Jeppsson A; Bjerke M; Hellström P; Blennow K; Zetterberg H; Kettunen P; Wikkelsø C; Wallin A; Tullberg M Front Neurol; 2022; 13():839307. PubMed ID: 35309577 [TBL] [Abstract][Full Text] [Related]
9. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902 [TBL] [Abstract][Full Text] [Related]
10. Patients with the Subcortical Small Vessel Type of Dementia Have Disturbed Cardiometabolic Risk Profile. Axelsson E; Wallin A; Svensson J J Alzheimers Dis; 2020; 73(4):1373-1383. PubMed ID: 31929169 [TBL] [Abstract][Full Text] [Related]
11. Vascular disease, Alzheimer's disease biomarkers and cognition in mild cognitive impairment: additive or synergetic effects? Nordlund A; Göthlin M; Wallin A Dement Geriatr Cogn Disord; 2011; 32(4):250-6. PubMed ID: 22179302 [TBL] [Abstract][Full Text] [Related]
12. Effects of APOE ε4 on brain amyloid, lacunar infarcts, and white matter lesions: a study among patients with subcortical vascular cognitive impairment. Kim HJ; Ye BS; Yoon CW; Cho H; Noh Y; Kim GH; Choi YS; Kim JH; Jeon S; Lee JM; Kim JS; Choe YS; Lee KH; Kim ST; Kim C; Kang DR; Ki CS; Lee JH; Werring DJ; Weiner MW; Na DL; Seo SW Neurobiol Aging; 2013 Nov; 34(11):2482-7. PubMed ID: 23769398 [TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792 [TBL] [Abstract][Full Text] [Related]
14. Update on the Neurobiology of Vascular Cognitive Impairment: From Lab to Clinic. Vinciguerra L; Lanza G; Puglisi V; Fisicaro F; Pennisi M; Bella R; Cantone M Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340195 [TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O; JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [TBL] [Abstract][Full Text] [Related]
16. Plasma β-amyloid in Alzheimer's disease and vascular disease. Janelidze S; Stomrud E; Palmqvist S; Zetterberg H; van Westen D; Jeromin A; Song L; Hanlon D; Tan Hehir CA; Baker D; Blennow K; Hansson O Sci Rep; 2016 May; 6():26801. PubMed ID: 27241045 [TBL] [Abstract][Full Text] [Related]